Board of Directors
Lynnor Stevenson Ph.D.
Lynnor is a successful entrepreneur with thirty years experience in the formation and growth of bioscience companies. She was a member of the early-stage teams for Heska Corporation, Creative BioMolecules (now Curis), AP Pharma, Agen and Univax (now Nabi), and has served on the board of several biotech companies. In addition to business and R&D experience relating to drugs, vaccines and diagnostics, she has experience in drug development at several companies including the submission of several IND (Investigational New Drug) applications to the FDA.
Erik is Managing Director of the Wisconsin Alumni Research Foundation (WARF). His extensive international life sciences deal-making expertise has been developed during an extensive career focused largely in global health. He was formerly in Seattle serving as President of the Infectious Disease Research
Joseph is an angel investor and currently is on the Board of Bellingham Angel Investors. His career has included founding startup companies and commercialization consulting with RPX Group, where he was a Managing Director. His career has also included stints as a corporate attorney and an engineer.
Dr. David Peyton Ph.D.
Corporate Secretary, Chief Scientific Officer
David is a Professor of Chemistry at Portland State University. He has carried out research in areas ranging from NMR methods development to biological chemistry, and has been working on infectious disease and malaria drug action for over 15 years. His work on parasites began in 1992 with NMR-based studies of anti-malarial drug action.
Sandra Shotwell Ph.D.
Sandra has over 25 years of experience in early stage technology commercialization. She has co-founded three companies, and has done biotech deals for Stanford University, Oregon Health Sciences University, and the National Institutes of Health, where she founded and led the technology licensing program. Sandra is Board Chair of Elex Biotech, a company developing drugs to manage cardiac arrhythmia. She also was a Managing Partner of Alta Biomedical Group, a consulting firm focusing on the commercialization of innovative technology.
James is an expert in clinical development, having managed clinical trials on behalf of dozens of biopharmaceutical companies worldwide. Serving as both Chief Business and Chief Operations Officer at Clinimetrics, he joined founder Brad Zaro as equity partner to incorporate and grow Clinimetrics into a global, full-service, clinical Contract Research Organization (CRO) with over 400 employees worldwide before the company was acquired by Fortune 500 health care company, Omnicare.